$2.67
▲ +0.4% Today
as of Sep 4, 16:53 ET
Last 30 days
Recent Press Releases & News
Protalix BioTherapeutics, Inc. Q2 2026 Earnings Call Summary
PLX: Elfabrio Estimates Up
Protalix BioTherapeutics Inc (PLX) (Q2 2026) Earnings Call Highlights: Net Income Surges to $3. ...
Overview
52-week range
$1.52
$3.19
69% of range
Avg surprise (last 3)
+679.2%
Avg reaction (last 2)
-19.7%
50% positive
Latest IV / EM
120%
EM ±18.7% · $3 · Sep 18
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | $0.05 | — | — | — | — | financials |
| Wed May 13, 2026 | Mar/2026 | $0.22 | $-0.01 | +2,300% | +540.0% | +1.0% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $0.03 | — | — | — | — | financials |
| Thu Aug 14, 2025 | Jun/2025 | — | $0.03 | -100.0% | — | — | earnings |
| Fri May 9, 2025 | Mar/2025 | $-0.05 | $0.08 | -162.5% | — | -40.5% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $0.03 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.03 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.06 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.04 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $0.21 | — | — | — | — | financials |
| Fri Mar 31, 2023 | Mar 2023 | $-0.05 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $20M | $34M | — | $18M | $16M | $10M | — | $18M |
| Cost of revenue | $8M | $4M | — | $8M | $6M | $8M | — | $8M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $5M | $21M | — | $2M | $1M | $-4M | — | $4M |
| Net income | $4M | $18M | — | $2M | $164,000 | $-4M | — | $3M |
| EPS (diluted) | $0.05 | $0.22 | — | $0.03 | — | $-0.05 | — | $0.03 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $27M | $41M | $15M | $14M | $18M | $19M | $20M | $27M |
| Inventory | $32M | $30M | $26M | $21M | $21M | $20M | $21M | $17M |
| Total current assets | $92M | $86M | $67M | $67M | $65M | $61M | $60M | $48M |
| Total assets | $110M | $102M | $82M | $82M | $78M | $74M | $73M | $62M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $39M | $35M | $34M | $29M | $29M | $29M | $30M | $29M |
| Total equity | $71M | $67M | $48M | $53M | $50M | $45M | $43M | $32M |